BLU-667 Promising in RET-Altered Solid Tumors

BLU-667 Promising in RET-Altered Solid Tumors

Doses of at least 60 mg yielded tumor reductions of 2% to 70% among 25 of the 30 evaluated patients.

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

At the time of final analysis, 192 of 302 patients had died.

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

Improvement in RFS was seen regardless of PD-L1 status.

Rotavirus Vaccine May Overcome Immunotherapy Resistance

Rotavirus Vaccine May Overcome Immunotherapy Resistance

Researchers infected various tumor cell lines with anti-rotavirus vaccines confirmed to be PRR agonists.

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.

Tumor Cell Lysate Vaccine Shows Promise

Tumor Cell Lysate Vaccine Shows Promise

Antigen-specific T cells increased in frequency in vaccinated mice.

FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC

FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC

The FDA granted breakthrough therapy designation to durvalumab for patients with locally advanced, unresectable NSCLC who do not relapse after platinum-based chemoradiation.

Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

The addition of galunisertib to gemcitabine demonstrated improved overall and progression-free survival in pancreatic cancer.

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cells were determined to be safe for further study in patients with refractory aggressive non-Hodgkin lymphoma.

Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

Neoadjuvant ado-trastuzumab emtansine (T-DM1) combined with pertuzumab substantially improved pathologic complete response rates.

Labetuzumab Govitecan Active in Heavily Pretreated mCRC

Labetuzumab Govitecan Active in Heavily Pretreated mCRC

Monotherapy with labetuzumab govitecan is active in heavily pretreated patients with metastatic colorectal cancer (mCRC).

Entinostat May Improve Benefit of High-dose IL-2 in RCC

Entinostat May Improve Benefit of High-dose IL-2 in RCC

Entinostat may synergistically improve the therapeutic effect of high dose interleukin-2 (IL-2) in treatment-naïve clear cell renal cell carcinoma (RCC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs